Biden administration asks U.S. Supreme Court to shun Bayer weedkiller
appeal
Send a link to a friend
[May 11, 2022] WASHINGTON
(Reuters) -President Joe Biden's administration on Tuesday asked the
U.S. Supreme Court not to hear Bayer's bid to dismiss claims by
customers who contend that its Roundup weedkiller causes cancer, as the
company seeks to avoid potentially billions of dollars in damages.
Solicitor General Elizabeth Prelogar, who represents the administration
before the high court, said in a court filing that Bayer's appeal should
be rejected.
Bayer shares on Wednesday plunged 6.3%, a loss of about 3.7 billion
euros ($3.9 billion) in market value, to their lowest in seven weeks at
0735 GMT as traders dismissed any likelihood of the company's case being
heard.
The stock is still up more than 20% this year on a rebound in demand
from farmers.
Bayer last August petitioned the justices to reverse a lower court's
decision that upheld $25 million in damages awarded to California
resident Edwin Hardeman, a Roundup user who blamed his cancer on the
German pharmaceutical and chemical giant's glyphosate-based weedkillers.
The Supreme Court in December asked Biden's administration to provide
its views. The justices generally give deference to the solicitor
general's conclusions.
Bayer has argued that the cancer claims over Roundup and its active
ingredient glyphosate go against sound science and product clearance
from the U.S. Environmental Protection Agency. The EPA has upheld
guidance that glyphosate is not carcinogenic and not a risk to public
health when used as indicated on the label.
The lawsuits against Bayer have said the company should have warned
customers of the alleged cancer risk.
Prelogar rejected Bayer's argument that the EPA label approval under a
federal law called the Federal Insecticide, Fungicide and Rodenticide
Act preempts the "failure to warn" claims brought under state law.
"EPA's approval of labeling that does not warn about particular chronic
risks does not by itself preempt a state-law requirement to provide such
warnings," Prelogar wrote.
The Supreme Court's decision on whether to take up the matter is being
closely watched as Bayer maneuvers to limit its legal liability in
thousands of cases.
A company statement said Bayer believes it has "strong legal arguments"
to support the Supreme Court taking up the case.
[to top of second column]
|
A person walks down the sidewalk near the U.S. Supreme Court
building in Washington, D.C., U.S., February 16, 2022. REUTERS/Jon
Cherry/File Photo
Roundup-related lawsuits have dogged Bayer since it
acquired the brand as part of its $63 billion purchase of
agricultural seeds and pesticides maker Monsanto in 2018.
Despite the recent share price recovery, all of Bayer only has a
market value of about what it paid for Monsanto, burdened by the
litigation.
Bayer struck a settlement deal in principle with plaintiffs two
years ago but failed to win court approval for a separate agreement
on how to handle future cases.
In July, Bayer took an additional litigation provision of $4.5
billion in case of an unfavorable ruling by the Supreme Court or in
case the justices declined to consider its petition.
The provision came on top of $11.6 billion it previously set aside
for settlements and litigation over the matter.
Bayer plans to replace glyphosate in weedkillers for the U.S.
residential market for non-professional gardeners with other active
ingredients.
It has said it will continue to sell the herbicide to farmers, who
rely on it heavily and whose role in the litigation has been
described as negligible by Bayer.
Bayer has put on hold the settlement of about 30,000 cases, out of
125,000 cases overall, as it awaits decisions by the Supreme Court.
Bayer had asked the Supreme Court to review the verdict in
Hardeman's case, which was upheld by the San Francisco-based 9th
U.S. Circuit Court of Appeals in May.
Hardeman had regularly used Roundup for 26 years at his home in
northern California before being diagnosed with a form of
non-Hodgkin's lymphoma.
($1 = 0.9474 euros)
(Reporting by Lawrence Hurley in Washington and Ludwig Burger in
Frankfurt; Editing by Will Dunham and Christian Schmollinger)
[© 2022 Thomson Reuters. All rights
reserved.]
This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |